INVA - Innoviva, Inc.
11.08 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 11.40 |
| Open | 11.34 |
| Bid | 11.07 x 2200 |
| Ask | 11.08 x 1400 |
| Day's Range | 11.05 - 11.51 |
| 52 Week Range | 10.93 - 20.54 |
| Volume | 325,427 |
| Avg. Volume | 742,421 |
| Market Cap | 1.122B |
| Beta (3Y Monthly) | 0.35 |
| PE Ratio (TTM) | 3.24 |
| EPS (TTM) | 3.42 |
| Earnings Date | Oct 29, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2015-09-08 |
| 1y Target Est | 15.00 |
- Business Wire
Innoviva Reports Second Quarter 2019 Financial Results
BRISBANE, Calif.-- -- Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. today reported financial results for the second quarter ended June 30, 2019. Gross royalty revenues of $67.6 million ...
- Zacks
Moleculin Files New Patents for Cancer Candidate Annamycin
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
- Simply Wall St.
Does The Data Make Innoviva, Inc. (NASDAQ:INVA) An Attractive Investment?
I've been keeping an eye on Innoviva, Inc. (NASDAQ:INVA) because I'm attracted to its fundamentals. Looking at the...
- Zacks
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Markit
See what the IHS Markit Score report has to say about Innoviva Inc.
Innoviva Inc NASDAQ/NGS:INVAView full report here! Summary * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 12. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold INVA had net inflows of $2.63 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.
How Does Innoviva, Inc. (NASDAQ:INVA) Affect Your Portfolio Volatility?
If you're interested in Innoviva, Inc. (NASDAQ:INVA), then you might want to consider its beta (a measure of share...
- Zacks
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
- Zacks
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
- Zacks
Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Reuters
GSK's 3-in-1 inhalable drug shows promise in asthma study
The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta. The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older medicines.
- Business Wire
Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint
GlaxoSmithKline plc and Innoviva, Inc. today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta compared to Relvar/Breo Ellipta , in the treatment of patients living with uncontrolled asthma.
- Associated Press
Innoviva: 1Q Earnings Snapshot
The Brisbane, California-based company said it had net income of 31 cents per share. The biopharmaceutical company posted revenue of $55.2 million in the period. Innoviva shares have decreased 20% since ...
- Business Wire
Innoviva Reports First Quarter 2019 Financial Results
BRISBANE, Calif.-- -- Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2019. Gross royalty revenues of $58.6 million ...
- Insider Monkey
Is Innoviva, Inc. (INVA) A Good Stock To Buy?
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- Simply Wall St.
Those Who Purchased Innoviva (NASDAQ:INVA) Shares Five Years Ago Have A 49% Loss To Show For It
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing and under-performing stocks...
- Motley Fool
3 Top Biotech Stocks to Buy in April
These three biotech stocks are worth buying this month.
- Simply Wall St.
How Many Insiders Bought Innoviva, Inc. (NASDAQ:INVA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
- GuruFocus.com
Innoviva Inc (INVA) Files 10-K for the Fiscal Year Ended on December 31, 2018
Innoviva Inc (NASDAQ:INVA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
